Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syntropharma advances transdermal drug patch with $2.4m

This article was originally published in Clinica

Executive Summary

Syntropharma is looking to complete development of its skin patch treatment for depression after securing £1.25m ($2.4m) in its second fundraising round. The transdermal patch will deliver reformulated Selegiline, an off-patent monamine oxidase inhibitor primarily indicated for depression, but which also has applications in Parkinson's disease. Newton St Boswells, Scottish Borders-based Syntropharma expects to submit trial data of the product to the US FDA by Q2 2009, with view of a product launch in 2010. The financing will also be used to advance its pipeline products, which include a drug patch for treating delusional psychosis and another for managing alcohol and opioid addictions. Investors in Syntropharma include Scottish Enterprise, Highland Venture Capital, LINC, Chimaera Bio and TRI Cap.

You may also be interested in...



Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.

Topics

UsernamePublicRestriction

Register

MT042469

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel